OTTAWA, June 6, 2011 /CNW/ - The following is a statement by Russell Williams, President of Canada's
Research-based Pharmaceutical Companies (Rx&D) on the Federal Budget
presented by Finance Minister Jim Flaherty on June 6, 2011 and on the
Speech from the Throne of June 3, 2011.
"As the industry that discovers and develops the medicines and vaccines
that improve and save lives, we welcome the direction taken in the
budget and the throne speech to spark innovation and promote health and
"We commend the Government of Canada's commitment to negotiate the
Comprehensive Economic and Trade Agreement (CETA) with the European
Union by 2012 which has the potential to create jobs and investment in
life sciences and the knowledge economy. CETA matters. It is crucial
that Canada improve its Intellectual Property Regime to levels already
enjoyed by the EU and other major trading partners.
"We applaud the Harper government's Shared Vision for Perimeter Security
and Economic Competitiveness with the U.S., especially the work of the
Regulatory Cooperation Council to harmonize regulations and reduce
unnecessary red tape.
"We are also encouraged by the government's support of up to $100
million to help establish a Canada Brain Research Fund which is
designed to put Canada at the forefront of scientific discovery to
improve the health and quality of life for Canadians who suffer from
"We support measures such as providing an additional $65 million for
Genome Canada to continue its ground breaking work as well as $37
million per year to support the three federal research granting
councils along with the creation of 10 new Canada Excellence Research
"We welcome the additional support for community based palliative care
which is welcome and necessary for patients and families who need care
and compassion at end of life.
"We cannot overstate the urgent need to take action to preserve life
sciences research and attract more jobs and investment in a fiercely
competitive global market.
"We look forward to working with all levels of government to deliver a
scientific innovation and knowledge agenda that will result in better
health and greater prosperity."
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: